Biomarker company Genialis and the Pancreatic Cancer Action Network (PanCAN) are collaborating to further the validation of the Genialis KrasID biomarker for pancreatic cancer using PanCAN's Know Your Tumor precision medicine service.
The partnership was announced at the 2024 American Society of Clinical Oncology Annual Meeting, which is being held in Chicago from May 31 to June 4.
KrasID is an RNA-based biomarker panel that integrates signals from KRAS biology with the surrounding tumor environment using RNA sequencing and machine learning to predict response and clinical benefit to KRAS inhibitors.
"The RAS gene family is the original white whale of cancer drug targets. Since the discovery of RAS genes and their role in promoting cancer over 40 years ago, patients, physicians, and cancer researchers have been on the hunt for a safe and effective drug against this behemoth. Yet, there are still limited treatment options," Rafael Rosengarten, PhD, CEO of Genialis, said. "Nowhere is mutated KRAS more prevalent than in pancreatic cancer. Through this partnership with PanCAN, Genialis hopes to play a part in advancing therapeutic options for patients very much in need of effective new medicines."
Overactivation of KRAS is implicated in up to 95% of pancreatic cancers, Genialis noted in a statement. This collaboration between Genialis and PanCAN aims to advance Genialis KrasID as a diagnostic tool to accelerate the development of new therapies, as well as assist physicians and patients in treatment planning.
